vs
AEHR TEST SYSTEMS（AEHR）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是AEHR TEST SYSTEMS的2.0倍（$19.6M vs $9.9M），AEHR TEST SYSTEMS净利率更高（-32.7% vs -177.4%，领先144.7%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -26.5%），AEHR TEST SYSTEMS自由现金流更多（$-1.6M vs $-23.1M），过去两年AEHR TEST SYSTEMS的营收复合增速更高（14.3% vs -12.2%）
Aehr Test Systems是全球半导体测试领域供应商，主要设计、生产和销售先进的半导体老化测试设备，服务于芯片制造商、封测厂商及芯片设计企业，产品用于逻辑芯片、存储芯片、功率半导体的可靠性验证，业务覆盖北美、亚洲、欧洲等主要市场。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
AEHR vs LAB — 直观对比
营收规模更大
LAB
是对方的2.0倍
$9.9M
营收增速更快
LAB
高出15.1%
-26.5%
净利率更高
AEHR
高出144.7%
-177.4%
自由现金流更多
AEHR
多$21.4M
$-23.1M
两年增速更快
AEHR
近两年复合增速
-12.2%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9M | $19.6M |
| 净利润 | $-3.2M | $-34.7M |
| 毛利率 | 25.7% | 48.5% |
| 营业利润率 | -47.0% | -168.5% |
| 净利率 | -32.7% | -177.4% |
| 营收同比 | -26.5% | -11.5% |
| 净利润同比 | -214.2% | -28.8% |
| 每股收益（稀释后） | $-0.11 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEHRLAB
| Q4 25 | $9.9M | — | ||
| Q3 25 | $11.0M | $19.6M | ||
| Q2 25 | $14.1M | $21.8M | ||
| Q1 25 | $18.3M | $40.8M | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $13.1M | $22.1M | ||
| Q2 24 | $16.6M | $22.5M | ||
| Q1 24 | $7.6M | $45.5M |
净利润AEHRLAB
| Q4 25 | $-3.2M | — | ||
| Q3 25 | $-2.1M | $-34.7M | ||
| Q2 25 | $-2.9M | $-33.5M | ||
| Q1 25 | $-643.0K | $-26.0M | ||
| Q4 24 | $-1.0M | — | ||
| Q3 24 | $660.0K | $-26.9M | ||
| Q2 24 | $23.9M | $-45.7M | ||
| Q1 24 | $-1.5M | $-32.2M |
毛利率AEHRLAB
| Q4 25 | 25.7% | — | ||
| Q3 25 | 33.9% | 48.5% | ||
| Q2 25 | 30.3% | 48.8% | ||
| Q1 25 | 39.2% | 48.4% | ||
| Q4 24 | 40.1% | — | ||
| Q3 24 | 54.0% | 54.9% | ||
| Q2 24 | 50.9% | 46.1% | ||
| Q1 24 | 41.7% | 53.1% |
营业利润率AEHRLAB
| Q4 25 | -47.0% | — | ||
| Q3 25 | -37.1% | -168.5% | ||
| Q2 25 | -22.7% | -118.1% | ||
| Q1 25 | -6.1% | -80.8% | ||
| Q4 24 | -11.2% | — | ||
| Q3 24 | 1.2% | -120.9% | ||
| Q2 24 | 15.3% | -134.5% | ||
| Q1 24 | -27.1% | -132.2% |
净利率AEHRLAB
| Q4 25 | -32.7% | — | ||
| Q3 25 | -19.0% | -177.4% | ||
| Q2 25 | -20.6% | -153.7% | ||
| Q1 25 | -3.5% | -63.8% | ||
| Q4 24 | -7.6% | — | ||
| Q3 24 | 5.0% | -122.0% | ||
| Q2 24 | 143.8% | -203.3% | ||
| Q1 24 | -19.4% | -70.6% |
每股收益（稀释后）AEHRLAB
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.07 | $-0.09 | ||
| Q2 25 | $-0.10 | $-0.09 | ||
| Q1 25 | $-0.02 | $-0.07 | ||
| Q4 24 | $-0.03 | — | ||
| Q3 24 | $0.02 | $-0.07 | ||
| Q2 24 | $0.81 | $-0.12 | ||
| Q1 24 | $-0.05 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $30.8M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $130.8M | $399.7M |
| 总资产 | $148.7M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AEHRLAB
| Q4 25 | $30.8M | — | ||
| Q3 25 | $22.7M | $129.4M | ||
| Q2 25 | $24.5M | $158.6M | ||
| Q1 25 | $29.4M | $150.9M | ||
| Q4 24 | $32.2M | — | ||
| Q3 24 | $37.8M | $210.6M | ||
| Q2 24 | $49.2M | $269.8M | ||
| Q1 24 | $47.6M | $287.1M |
总债务AEHRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $55.2M | ||
| Q2 24 | — | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益AEHRLAB
| Q4 25 | $130.8M | — | ||
| Q3 25 | $122.4M | $399.7M | ||
| Q2 25 | $122.9M | $424.5M | ||
| Q1 25 | $124.2M | $454.6M | ||
| Q4 24 | $123.2M | — | ||
| Q3 24 | $122.5M | $489.3M | ||
| Q2 24 | $111.6M | $510.3M | ||
| Q1 24 | $86.5M | $577.3M |
总资产AEHRLAB
| Q4 25 | $148.7M | — | ||
| Q3 25 | $144.1M | $539.6M | ||
| Q2 25 | $148.5M | $557.0M | ||
| Q1 25 | $145.6M | $579.6M | ||
| Q4 24 | $142.3M | — | ||
| Q3 24 | $145.9M | $681.5M | ||
| Q2 24 | $127.9M | $708.7M | ||
| Q1 24 | $101.6M | $777.7M |
负债/权益比AEHRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.11× | ||
| Q2 24 | — | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.2M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-1.6M | $-23.1M |
| 自由现金流率自由现金流/营收 | -16.6% | -118.1% |
| 资本支出强度资本支出/营收 | 4.7% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-11.7M | $-111.1M |
8季度趋势，按日历期对齐
经营现金流AEHRLAB
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-282.0K | $-22.2M | ||
| Q2 25 | $-2.3M | $-20.7M | ||
| Q1 25 | $-1.6M | $-30.3M | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $2.4M | $-27.9M | ||
| Q2 24 | $1.2M | $-39.0M | ||
| Q1 24 | $-2.8M | $-62.5M |
自由现金流AEHRLAB
| Q4 25 | $-1.6M | — | ||
| Q3 25 | $-1.7M | $-23.1M | ||
| Q2 25 | $-5.1M | $-22.6M | ||
| Q1 25 | $-3.3M | $-35.3M | ||
| Q4 24 | $-6.2M | — | ||
| Q3 24 | $2.2M | $-30.1M | ||
| Q2 24 | $1.2M | $-41.0M | ||
| Q1 24 | $-3.1M | $-63.3M |
自由现金流率AEHRLAB
| Q4 25 | -16.6% | — | ||
| Q3 25 | -15.3% | -118.1% | ||
| Q2 25 | -36.3% | -103.6% | ||
| Q1 25 | -17.8% | -86.6% | ||
| Q4 24 | -46.0% | — | ||
| Q3 24 | 16.6% | -136.4% | ||
| Q2 24 | 7.1% | -182.2% | ||
| Q1 24 | -40.8% | -138.9% |
资本支出强度AEHRLAB
| Q4 25 | 4.7% | — | ||
| Q3 25 | 12.7% | 4.5% | ||
| Q2 25 | 20.0% | 8.7% | ||
| Q1 25 | 9.0% | 12.4% | ||
| Q4 24 | 2.4% | — | ||
| Q3 24 | 1.5% | 10.2% | ||
| Q2 24 | 0.3% | 8.6% | ||
| Q1 24 | 3.5% | 1.7% |
现金转化率AEHRLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.61× | — | ||
| Q2 24 | 0.05× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AEHR
| Systems | $5.0M | 50% |
| Contactors | $3.4M | 35% |
| Services | $1.5M | 15% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
